

**CURRICULUM VITAE**  
**JUDITH I. TSUI, MD, MPH**

**1. ACADEMIC TRAINING:**

1986-1991 B.A., Princeton University, Princeton, NJ; magna cum laude, Anthropology  
1993-1997 M.D., New York University School of Medicine, New York City, NY  
2002-2004 M.P.H., Rollins School of Public Health, Emory University, Atlanta, GA

**2. POSTDOCTORAL TRAINING:**

1997-1998 Intern, Oregon Health Sciences University, Portland, OR  
1998-2000 Resident, Oregon Health Sciences University, Portland, OR  
2004-2006 Research Fellow in General Internal Medicine, University of California,  
San Francisco, CA  
2006-2008 CTSA K12 Scholar, University of California, San Francisco, CA

**3. ACADEMIC APPOINTMENTS:**

2000-2002 Instructor in Medicine, Emory University School of Medicine, Atlanta, GA  
2002-2004 Assistant Professor of Medicine, Emory University School of Medicine, Atlanta, GA  
2004-2008 Instructor in Medicine, San Francisco VA Medical Center, San Francisco, CA  
2008-2014 Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA  
2014-2016 Acting Assistant Professor of Medicine, University of Washington School of Medicine  
2016-current Associate Professor of Medicine, University of Washington School of Medicine, Seattle, WA

**4. HOSPITAL APPOINTMENTS:**

2000-2004 Attending Physician, Grady Memorial Hospital, Atlanta, GA  
2004-2008 Physician, San Francisco Veterans Affairs Administration, San Francisco, CA  
2008-2014 Attending Physician, Boston Medical Center, Boston, MA  
2014-current Attending Physician, Harborview Medical Center, Seattle, WA

**5. HONORS AND AWARDS:**

1991 Magna Cum Laude, Princeton University  
1994 Stanley Foundation Research Award, NYU School of Medicine  
2002 Internal Medicine Wards Attending Teaching Award,  
Emory University School of Medicine  
2006 Bay Area Clinical Research Symposium Finalist for Best Abstract  
2007 Bay Area Clinical Research Symposium Finalist for Best Poster  
2015 Research paper selected for NIDA "Director's Report," by Dr. Nora Volkow  
2016 Research paper selected for NIDA "Director's Report," by Dr. Nora Volkow  
2019 Outstanding Research Mentor Award, UW Medical School Class of 2017

**6. BOARD CERTIFICATION:**

2000 Certified, American Board of Internal Medicine (re-certified 2010, expires 12/31/2020)  
2013 Certified, American Board of Addiction Medicine (expired 12/31/2023)

**7. LICENSES TO PRACTICE**

1998 State of Oregon Medical License #LL08914  
2000 State of Georgia Medical License #48945  
2004 State of California Medical License #A88353  
2008 State of Massachusetts Medical License #236710  
2014 State of Washington Medical License #60511536

## **8. PROFESSIONAL ORGANIZATIONS**

- 2000-present Society of General Internal Medicine (SGIM)
- 2002-2010 American College of Physicians (ACP)
- 2013-2014 American Pain Society (APS)
- 2013-present American Society of Addiction Medicine (ASAM)
- 2013-present College on Problems of Drug Dependence (CPDD)
- 2014-present Association for Medical Education and Research on Substance Abuse (AMERSA)

## **9. TEACHING EXPERIENCE AND RESPONSIBILITIES**

- 2000-2004 Medical Clinic Attending Physician, Grady Hospital
- 2000-2004 Medical Ward Attending Physician, Grady Hospital
- 2004-2008 Medical Clinic Attending Physician, SFVAMC
- 2005-2006 Medical Ward Attending Physician, SFVAMC
- 2008-2014 Medical Ward Attending Physician, Boston Medical Center
- 2019-current Associate Program Director, UW/Harborview Addiction Medicine Fellowship

## **10. EDITORIAL RESPONSIBILITIES**

### **JOURNAL – EDITORIAL BOARDS:**

- 2012-2013 Associate Editor, *Alcohol, Other Drugs, and Health: Current Evidence*
- 2019-current Academic Editor, *Plos One*

### **JOURNAL REVIEWER:**

- American Journal of Kidney Disease
- American Journal of Public Health
- Annals of Internal Medicine
- Clinical Infectious Diseases
- Contemporary Clinical Trials
- Digestive Diseases and Sciences
- Drug and Alcohol Dependence
- International Journal of Drug Policy
- JAMA Internal Medicine
- JAIDS
- Journal of Addiction Medicine
- Journal of American Society of Nephrology
- Journal of Clinical Gastroenterology
- Journal of General Internal Medicine
- Journal of the International AIDS Society
- Journal of Substance Abuse Treatment
- Journal of Palliative Care
- Journal of Viral Hepatitis
- Pain Medicine
- Plos One

## **11. GRANT STUDY SECTIONS**

- NIH/NIDA study section ZRG1 AARR-H PAR Panel, December 10, 2015
- NIH/NIDA study section ZDA1 HXO-H Panel, November 30, 2018
- NIH/NIDA study section ZDA1 GXM-A Panel, February 19, 2019
- NIH/NIDDK study section ZDK1 GRB-M Panel, August 6, 2019

## 12. SPECIAL NATIONAL RESPONSIBILITIES

- 2004-2006 Founder and member, Society of General Internal Medicine HCV Interest Group  
2013-2014 Society of General Internal Medicine, National Meeting Scientific Abstract Reviewer  
2019-current Society for Behavioral Medicine Scientific Abstract Reviewer for Annual Meeting  
2019-current Global Task Force for Chronic Pain in People with HIV  
2019-current College for Problems of Drug Dependence Membership Committee

## 13. SPECIAL LOCAL RESPONSIBILITIES:

- 2002-2004 Member, Grady Memorial Hospital Pain Committee  
2002-2004 Grady Hospital Liver Clinic (providing hepatitis C care in primary care clinic)  
2008-2014 Buprenorphine Provider, Office Based Opioid Treatment (OBOT) Program, Boston Medical Center  
2011-2014 Founder, Hepatitis C Treatment OBOT Program, Boston Medical Center  
2014-2014 Co-Director, Hepatitis C virus transmission, outcomes, and healthcare delivery among substance users, Pre-Affinity Research Collaborative (Pre-ARC), Evans Center for Interdisciplinary Biomedical Research  
2015-present Founding member and physician provider of Harborview Medical Center's Office Based Opioid Treatment Program (OBOT) established 12/2015  
2016-present Founding member and physician provider of HMC's satellite primary care clinic at Evergreen Treatment Services, established 7/2016  
2016 Co-organizer with Dr. Lauren Beste of Resident Conference/Academic Half-Day on Hepatitis C  
2018 Member of the WA State Hepatitis C Elimination Coordinating Committee, assembled to assist Governor Jay Inslee achieve his statewide initiative to eliminate Hepatitis C by 2030  
2019 Member of the Center for AIDS Research Behavioral Science Steering Committee at the University of Washington, established 2/4/2019

## 14. RESEARCH FUNDING

### Current

1R01DA037768-03 (Samet/Del Rio) 09/01/14–08/31/20 0.24 CM  
NIH NIDA \$44,055 (Subaward)

### **Improving Physician Opioid Prescribing for Chronic Pain in HIV-infected Persons**

The objective of this multisite randomized controlled trial is to test whether a collaborative care intervention for physicians can improve the delivery of chronic opioid therapy for HIV-infected persons by increasing physician adherence to opioid prescribing guidelines, increasing physician satisfaction and confidence in prescribing chronic opioid therapy, and reducing prescription opioid misuse.

5UG1DA013714-16 (Donovan/Hatch-Maillette) 06/01/15–05/31/20 1.20 CM  
NIH NIDA \$965,258

### **Clinical Trials Network: Pacific Northwest Node**

The major goal of this project is to conduct studies of the therapeutic effect of behavioral, pharmacological and combined/integrated treatment interventions in rigorous, multi-site clinical trials to determine the effectiveness across a broad range of community-based treatment settings and diversified populations, and to ensure the transfer of research results to physicians, clinicians, providers, policy makers, and patients.

HPC-1503-28122 (Litwin) 02/01/16–01/31/21 0.90 CM  
PCORI \$234,422 (Subaward)

### **Patient-Centered Models of HCV Care for People who Inject Drugs**

This study aims to explore the best model of care for treating hepatitis C (HCV) in people who inject drugs (PWID). This study will test multiple methods of HCV treatment. Outcomes to be evaluated will be treatment effectiveness (cure or sustained virological response) and reinfection rates. This will be a national study involving eight US cities (New York, Baltimore, Providence, Boston, Cincinnati, Seattle, San Francisco, and Albuquerque) and up to 1,000 PWIDs.

U01AA020793 (Crane/Lau) 09/01/16–08/31/21 0.60 CM  
NIH NIAAA \$568,690

**3/4 Alcohol Research Consortium in HIV – Epidemiological Research Arm (ARCH-ERA)**

ARCH-ERA was formed to investigate short and long-term effects of alcohol on clinical outcomes in the CFAR Network of Integrated Clinical Systems (CNICS). Capitalizing on the resources and infrastructure of CNICS, we propose to examine longitudinal relationships of alcohol use, co-morbid drug use, and mental health disorders on the HIV Care Continuum; to determine longitudinal relationships between alcohol and liver disease progression in the era of direct acting antivirals for hepatitis C virus treatment on liver disease outcomes; and to determine the impact of alcohol use on age-related comorbidities among PLWH in care.

R44DA044053 (Seiguer/Tsui) 06/01/17–06/30/20 0.90 CM  
NIH NIDA \$116,685 (Subaward)

**Development and Evaluation of Effectiveness of Video-Based Directly Observed Therapy for Office-Based Treatment of Opioid Use Disorders with Buprenorphine**

The goal of this project is to partner with private industry (emocha Mobile Health, Inc.) to develop a mobile phone application for video-based directly observed therapy for office-based treatment of opioid use disorders. The effectiveness of this treatment option will then be evaluated.

UH2AA026193 (Samet/Tsui) 09/20/17–08/31/22 1.20 CM  
Boston Medical Center/NIH NIAAA \$63,557 (Subaward)

**Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation among HIV-Infected Persons with Alcohol**

This study will pilot test novel pharmacotherapies (opioid receptor antagonists) to improve chronic pain among HIV-infected unhealthy drinkers, and will explore whether the mechanism of action is through decreased inflammation. The research will be performed in St. Petersburg, Russia, which is ideal given that 1) pharmacologic treatments for pain are limited (as there are strict regulations against the use of opioids for chronic pain), 2) there is high prevalence of heavy drinking and HIV, and 3) nalmefene (one of the opioid receptor antagonists to be studied) is licensed in Russia, not in the US.

1R01DA047045-01 (Crane/Peter) 08/01/18–05/31/23 0.45 CM  
NIH NIDA \$642,867

**Genes, substance use, and HIV outcomes in people living with HIV across the US**

The proposed research will identify genetic variants that contribute to outcomes including poorer responses to and greater toxicities from antiretroviral therapy among all people living with HIV and particularly including current and prior injection drug users.

1H79TI081651-01 (Klein/Tsui) 09/30/18–09/29/21 0.30 CM  
SAMHSA \$137,182

**University of Washington Provider's Clinical Support System – Universities**

The UW-PCSS-U project will provide DATA waiver training to medical students and residents with the goal of encouraging fledgling physicians to utilize buprenorphine in the treatment of opioid use disorder (OUD). To accomplish this goal, we will build on our institution's existing curriculum that addresses pain and addiction, including pre-clinical and clinical experiences.

1U24DA048538-01 (Crane/Tsui) 04/01/19–03/31/24 1.68 CM  
NIH \$473,225

**Rural Comorbidity and HIV consequences of Opioid use Research and Treatment Initiative (Rural cohort)**

Longitudinal studies are key to understand the evolving and increasingly rural opioid epidemic in the United States. Individual studies are addressing key questions regarding opioid use and its consequences in the United States but cannot address many of the important questions related to HIV risk and other consequences which require larger sample sizes and greater generalizability. By integrating and linking data across studies we will achieve the sample sizes needed to better understand the consequences, impacts, and other lessons that can be learned regarding opioid use in rural communities.

R25-DA037756 (Fairbairn) 04/01/19–03/31/24 0.60 CM  
University of British Columbia/NIH \$23,909 (Subaward)

**HIV researchers mentoring the next generation of addiction clinician scientists** funds an addiction medicine fellowship program that has already proven to be well-received and highly successful at bridging the gap between evidence-based medicine and clinical practice. It immerses fellows in research, complemented by formal academic training in evidence-based medicine, in order to prepare them for highly successful careers as addiction medicine clinician scientists.

IIR-17-120-3 (Williams) 07/01/19–07/01/21 0.34 CM  
Puget Sound Healthcare System VA \$7,500 (Subaward)

**Evaluating Practice Facilitation to Optimize Alcohol-Related Care and HCV Treatment Outcomes in HCV Treatment Settings**

This study aims primarily to increase provision of alcohol-related care in Hepatology clinics where Hepatitis C and other liver conditions influenced by alcohol use are treated, and secondarily to improve alcohol and liver condition outcomes. We will use qualitative methods to tailor a practice facilitation intervention and then use a Hybrid Type III design to evaluate the effectiveness of the intervention on implementation (primary) and clinical (secondary) outcomes.

P30AI027757 (Simoni) 06/01/18–05/30/23 0.60 CM  
NIH/NIAID \$111,733

**University of Washington/Fred Hutch Center for AIDS Research**

The UW/FH Center for AIDS Research fosters collaborative and interdisciplinary research, supports HIV research career development of young investigators, and serves HIV investigators at our affiliated institutions.

1R34DA047660-01 (Tsui) 08/01/19–06/30/22 1.20 CM  
NIH \$138,000

**Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV among Persons Who Inject Drugs**

The purpose of the research is to develop and pilot a community-pharmacy based model of care for persons who inject drugs that can offer treatment for HCV, in addition to medications to prevent overdose and HIV. The proposed research would lead to a future multi-site effectiveness study that will utilize existing community-based pharmacies throughout WA State to achieve HCV elimination.

R01AT011742-01 (Price/Merrill) 3/1/18-2/28/22 De Minimis  
NIH \$200,600

**Mindful Body Awareness Training as an Adjunct to Medication Assisted Treatment for Opioid Use Disorder.** This study of Mindful Awareness in Body-oriented Therapy (MABT) as an adjunct to Medication-

Assisted Treatment (MAT) of opioid use disorder (OUD) uniquely addresses aspects of awareness, interoception, and regulation that may be associated with pain, mental health distress, and behavioral control that increase risk of relapse and poor treatment outcomes; the results will directly inform treatment and are expected to contribute to integrative care in response to the opioid epidemic.

Pending

1R25DA050985-01 (Tsui) 04/01/20–03/31/25 2.16 CM  
NIH/NIDA \$339,915

**The UW Medical Student Addiction Research (MedStAR) Program to Address Substance Use and Disorders in Urban and Rural Communities in Five Western States**

The application proposes to create the UW Medical Student Addiction Research (MedStAR) program to provide opportunities for mentored research and clinical training for medical students in 5 western rural-serving states who are interested pursuing fellowship training and careers in Addiction Medicine and research. The MedStAR program will develop a “pipeline” of physicians who are poised to become the next generation of clinicians scientists to discover and implement evidence-based care for patients with substance use disorders.

Number Pending (Walters) 07/01/20–6/30/25 0.24 CM  
NIH \$249,999

**Indigenous Substance use Prevention Interdisciplinary Research Education Program**

Despite glaring health and HIV/AIDS-disparities among American Indian and Alaska Natives, Native Hawaiians, and other Pacific Island Islanders, there is a paucity of culturally grounded research addressing their HIV-related behavioral health concerns. A strong network of highly trained and productive Indigenous scholars dedicated to HIV/AIDS disparities and prevention research that is culturally grounded would contribute to ameliorating HIV-related disparities among Indigenous populations.

Previous

3UG1DA040314-03S3 (Campbell/ Bradley/Weisner) 11/01/17–05/31/19 0.30 CM  
NIH NIDA \$24,497 (Subaward)

**Integrating Addiction Research in Health Systems: The Addiction Research Network**

The primary objective of the PROUD trial is to evaluate whether implementation of the Massachusetts Model of collaborative care for management of opioid use disorders in primary care (the “PROUD intervention”) increases opioid use disorder treatment with buprenorphine or naltrexone over a 2 year follow-up, as compared to usual primary care.

1R01DA040386 (Hladik) 07/01/15–05/31/19 0.60 CM  
NIH NIDA \$366,221

**Extracellular Vesicles in Semen and Genital HIV Infection and Immunity during Heroin Addiction and Methadone or Buprenorphine Substitution Therapy**

This study investigates the interplay of extracellular vesicles in semen and opioid use and its consequences for HIV infection and the immune system.

UG3DA044831 (Korthuis) 10/01/17–03/31/19 0.36 CM  
OHSU/NIH NIDA \$10,895 (Subaward)

**Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study**

This proposal leverages and extends recent office-based opioid treatment and ECHO resources supporting OUD, HIV, and HCV treatment in Oregon and adds a novel approach to care management. We propose a novel,

multifaceted intervention to decrease HIV and HCV risk among people who inject drugs (PWID) in high-risk rural Oregon counties, by employing peer navigators as rural care coordinators. Peer navigators engage PWID networks, offer syringe exchange, and link PWID to testing, treatment, and harm reduction services. This novel intervention combines with expansion of existing primary care OBOT and ECHO initiatives to support rural primary care providers in treating HIV, HCV, and OUD to further reduce the risk of HIV transmission.

No grant # assigned (Banta-Green) 08/01/16–11/30/18  
Laura and John Arnold Foundation \$49,422

**WA State Innovation Initiative – Medication Assisted Treatment Upon Release from Prison**

The goal of this research is to develop an innovation initiative to better meet the needs of opioid dependent offenders and improve a broad set of outcomes for those releasing to the community from Washington Department of Correction (WA DOC) prison facilities. We will develop, implement and assess the feasibility of procedures to provide effective services for offenders with OUD releasing from WA DOC prisons.

1512-47681 (Merrill) 08/01/15–07/31/18  
SAMHSA \$172,436

**SAMHSA Medication-Assisted Treatment**

The MAT Prescription Drug and Opioid Addiction project provides clinical services through the Adult Medicine Clinic for patients suffering from opioid use disorders. Services will include Nurse Care Manager visits, buprenorphine prescribing and integrated primary medical care through physicians in the Adult Medicine Clinic, and integrated mental health support through the Mental Health Integration Program (MHIP).

No grant # assigned (Tsui) 06/01/17–05/31/18  
University of Washington \$30,000  
Alcohol & Drug Abuse Institute

**Qualitative Study of Patient and Provider Attitudes Toward Video-Based Directly Observed Therapy (vDOT) for Office-Based Treatment of Opioid Use Disorders with Buprenorphine**

The proposed study will conduct preliminary qualitative research to inform the development of video-based directly observed therapy (DOT) in office-based buprenorphine programs to improve care during initial months of treatment. Video-based DOT offers the benefit of patient and provider convenience by removing the need for frequent, in-person visits and has the potential for reduced stigma from a disease that disproportionately affects vulnerable populations.

5R25DA033211-05 (Samet, O'Connor) 04/01/12–03/31/18  
NIH NIDA \$15,846 (Subaward)

**Advancing Clinical Research Training within Addiction Residency Programs**

The objective of this grant is to develop a Research in Addiction Medicine Scholars (RAMS) Program. The RAMS Program is significant because it will expand the nation's research capacity among trainees in the new medical specialty of Addiction Medicine. This seeks ultimately to improve patient care by increasing knowledge about effective prevention and treatment in order to reduce the medical, social, and financial burden of drug abuse and addiction.

U01AA021989-05S1 (Samet) 09/15/16–08/31/17  
NIH NIAAA \$11,597 (Subaward)

**Zinc for HIV Disease among Alcohol Users – An RCT in the Russia ARCH Cohort**

The goal of this administrative supplement for gender-related research is to understand the opportunities for Pre-Exposure Prophylaxis (PrEP) among HIV-infected women in Russia, who inject drugs and use alcohol. The results of this study will be used to design a pilot partners study of HIV-serodiscordant couples which will recruit the HIV-uninfected female partners of HIV-infected men in Russia ARCH.

5R01DA031056-06 (Page)  
NIH NIDA

05/15/11–04/30/16  
\$40,615 (Subaward)

**International Collaborative of Prospective Studies of HIV and Hepatitis in IDU**

The research goal of this grant is to understand how substance use impacts hepatitis C spontaneous viral clearance among female compared to male people who inject drugs. Substance use can have a profound impact on sex hormones that, in part, may mediate sex-based differences in hepatitis C clearance. Therefore, there is biologic plausibility that relationships between substance use and hepatitis C clearance may differ between females and males.

5K23DA027367-04 (Tsui)  
NIH NIDA

06/01/10–05/31/15  
\$149,975

**HCV and Pain in Substance Users with and without HIV**

The central goal of this K23 was to examine how viral infections such as HCV and HIV impact risk for developing chronic pain and painful conditions in substance using populations. This research studied the novel hypotheses that HCV is associated with hypersensitivity to pain under experimental conditions and clinical pain.

R01DA032082 (Samet)  
NIH NIDA

07/15/11–04/30/15  
\$467,912

**Linking Russian Narcology & HIV Care to Enhance Treatment, Retention, & Outcomes (LINC)**

The study's goal was to improve upon current seek, test, treat, and retain efforts for HIV-infected Russian and Eastern European IDUs in narcology care, a group routinely tested for HIV. LINC was a behavioral and structural intervention designed to support and motivate HIV-infected narcology heroin dependent patients (i.e., IDUs) to engage (i.e., initiate and retain) in HIV medical care and ultimately improve their HIV

**15. BIBLIOGRAPHY**

**ORIGINAL, PEER-REVIEWED MANUSCRIPTS**

1. **Tsui JI**, Dodson K, Jacobson TA. Cardiovascular disease prevention counseling in residency: resident and attending physician attitudes and practices. *J Natl Med Assoc.* 2004;96(8):1080-3:1088-91. PMID: PMC2568499.
2. **Tsui JI**, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. *J Hepatol.* 2006;44(2):262-6. PMID: 16226823.
3. **Tsui JI**, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. *J Am Soc Nephrol.* 2006;17(4):1168-74. PMID: 16524948.
4. **Tsui JI**, Bangsberg DR, Ragland K, Hall CS, Riley ED. The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV. *AIDS Behav.* 2007;11(4):603-10. PMID: 17028996.
5. **Tsui JI**, Saitz R, Cheng DM, Nunes D, Libman H, Alperen JK, Samet JH. Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV. *J Gen Intern Med.* 2007;22(6):822-5. PMID: PMC2048689.
6. **Tsui JI**, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, O'Hare AM. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. *Arch Intern Med.* 2007;167(12):1271-6. PMID: 17592100.\*
7. **Tsui JI**, French AL, Seaberg EC, Augenbraun M, Nowicki M, Peters M, Tien PC. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. *Clin Infect Dis.* 2007;45(6):736-40. PMID: PMC4142488.



8. **Tsui JI**, Currie S, Shen H, Bini EJ, Brau N, Wright TL; VA HCV-001 Study Group. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. *Dig Dis Sci.* 2008;53(3):809-14. PMID: 17823868.
9. **Tsui JI**, Maselli J, Gonzales R. Sociodemographic trends in national ambulatory care visits for hepatitis C virus infection. *Dig Dis Sci.* 2009;54(12):2694-8. PMID: PMC2778662.
10. **Tsui J**, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, Cohen MH, Peters MG, Golub ET, Szczech L. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study. *Am J Kidney Dis.* 2009;54(1):43-50. PMID: PMC2997705.
11. **Tsui JI**, Whooley MA, Monto A, Seal K, Tien PC, Shlipak M. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. *J Card Fail.* 2009;15(5):451-6. PMID: PMC2782758.
12. **Tsui JI**, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K. Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. *Drug Alcohol Depend.* 2009;105(1-2):160-3. PMID: PMC2849721.\*
13. **Tsui JI**, Herman DS, Kettavong M, Alford D, Anderson BJ, Stein MD. Physician introduction to opioids for pain among patients with opioid dependence and depressive symptoms. *J Subst Abuse Treat.* 2010;39(4):378-83. PMID: PMC3129653.
14. **Tsui JI**, Herman DS, Kettavong M, Anderson BJ, Stein MD. Chronic pain and hepatitis C virus infection in opioid dependent injection drug users. *J Addict Dis.* 2011;30(2):91-7. PMID: PMC3089758.
15. **Tsui JI**, Herman DS, Kettavong M, Anderson BJ, Stein MD. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. *Pain.* 2011;152(11):2640-4. PMID: PMC3235744.
16. Evans JL, **Tsui JI**, Hahn JA, Davidson PJ, Lum PJ, Page K. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO Study. *Am J Epidemiol.* 2012;175(4):302-8. PMID: PMC3271816.
17. **Tsui JI**, Cheng DM, Libman H, Bridden C, Samet JH. Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults. *AIDS Care.* 2012;24(7):820-7. PMID: PMC3370099.
18. **Tsui JI**, Cheng DM, Libman H, Bridden C, Saitz R, Samet JH. Risky alcohol use and serum aminotransferase levels in HIV-infected adults with and without hepatitis C. *J Stud Alcohol Drugs.* 2013;74(2):266-70. PMID: PMC3568165.
19. Fuster D, **Tsui JI**, Cheng DM, Quinn EK, Armah KA, Nunes D, Freiberg MS, Samet JH. Interleukin-6 is associated with noninvasive markers of liver fibrosis in HIV-infected patients with alcohol problems. *AIDS Res Hum Retroviruses.* 2013;29(8):1110-16. PMID: PMC3715787.
20. Fuster D, **Tsui JI**, Cheng DM, Quinn EK, Bridden C, Nunes D, Libman H, Saitz R, Samet JH. Impact of lifetime alcohol use on liver fibrosis in a population of HIV-infected patients with and without hepatitis C coinfection. *Alcohol Clin Exp Res.* 2013;37(9):1527-35. PMID: PMC3758457.
21. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with heroin use over time in HIV-infected Russian drinkers. *Addiction.* 2013;108(10):1779-87. PMID: PMC4012755.
22. Meshesha LZ, **Tsui JI**, Liebschutz JM, Crooks D, Anderson BJ, Herman DM, Stein MD. Days of heroin use predict poor self-reported health in hospitalized heroin users. *Addict Behav.* 2013;38(12):2884-7. PMID: PMC3882159.
23. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, **Tsui JI**. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. *Addiction.* 2014;109(1):62-70. PMID: PMC3947001.
24. Fuster D, Cheng DM, Quinn EK, Armah KA, Saitz R, Freiberg MS, Samet JH, **Tsui JI**. Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems. *AIDS.* 2014;28(7):1059-64. PMID: PMC4105144.

25. **Tsui JI**, Cheng DM, Coleman SM, Lira MC, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with risky drinking over time among HIV-infected persons in St. Petersburg, Russia. *Drug Alcohol Depend.* 2014;144:87-92. PMID: PMC4252482.
26. **Tsui JI**, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. *JAMA Intern Med.* 2014;174(12):1974-81. PMID: PMC4506774.\*
27. **Tsui JI**, Anderson BJ, Strong DR, Stein MD. Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: a longitudinal study. *Am J Drug Alcohol Abuse.* 2014;40(2):163-9. PMID: PMC4868341.
28. Crooks D, **Tsui J**, Anderson B, Dossabhoy S, Herman D, Liebschutz JM, Stein MD. Differential risk factors for HIV drug and sex risk-taking among non-treatment-seeking hospitalized injection drug users. *AIDS Behav.* 2015;19(3):405-11. PMID: PMC4861062.
29. **Tsui JI**, Lira MC, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Mao J, Edwards RR, Samet JH. Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. *Drug Alcohol Depend.* 2015;153:286-92. PMID: PMC4509826.\*
30. Liebschutz JM, Crooks D, Herman D, Anderson BJ, **Tsui JI**, Meshesha LZ, Dossabhoy S, Stein MD. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. *JAMA Int Med.* 2014 Aug;174(8):1369-76. PMID: PMC4811188.
31. Page K, **Tsui JI**, Maher L, Choopanya K, Vanichseni S, Mock PA, Celum C, Martin M. Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: state of research and future directions. *J Acquir Immune Defic Syndr.* 2015 Jun 1;69 Suppl 2:S169-75. PMID: PMC4491435.
32. **Tsui JI**, Cheng DM, Sisson EK, Bridden C, Merlin JS, Saitz R, Samet JH. Pain and mortality risk in a cohort of HIV-infected persons with alcohol use disorders. *AIDS and Behaviors.* *AIDS Behav.* 2016 Mar;20(3):583-9. PMID: PMC4777650.
33. Carey K, Huang W, Linas BP, **Tsui JI**. Hepatitis C virus testing and treatment among persons receiving buprenorphine in an office-based program for opioid use disorders. *J Subst Abuse Treat.* 2016 Jul;66:54-9. PMID: PMC5097249.
34. **Tsui JI**, Lira M, Cheng DM, Winter MR, Alford DP, Liebschutz JM, Edwards RR, Samet JH. Chronic pain, craving, and illicit opioid use among patients receiving opioid agonist therapy. *Drug Alcohol Depend.* 2016 Sep 1;166:26-31. PMID: PMC4983520.
35. Ioannou GN, Beste LA, Chang MF, Green PK, Lowey E, **Tsui JI**, Su F, Berry K. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. *Gastroenterology.* 2016 Sep;151(3):457-471. PMID: PMC5341745.
36. **Tsui JI**, Ko S, Krupitsky E, Lioznov D, Chaisson CE, Gnatienco N, Samet JH. Insights on the Russian HCV care cascade: minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg. *Hepatol Med Policy.* 2016;1. PMID: PMC5313079.
37. **Tsui JI**, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. *Drug Alcohol Depend.* 2016 Dec 1;169:101-109. PMID: PMC6534140.
38. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Gnatienco N, Bryant K, Krupitsky E, Zvartau E, Samet JH. Pain and risk behaviors among HIV-infected persons in St. Petersburg, Russia. *AIDS Behav.* 2017 Jun;21(6):1775-1781. PMID: PMC5408303.
39. **Tsui JI**, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore G, Lauer G, Lloyd A, Page K. The effects of alcohol on spontaneous clearance of acute hepatitis c virus infection in females versus males. *Drug Alcohol Depend.* 2016 Dec 1;169:156-162. PMID: PMC5328754.

40. Lasser KE, Heinz A, Battisti L, Akoumianakis A, Truong V, **Tsui JI**, Ruiz G, Samet JH. A hepatitis C treatment program based in a safety-net hospital patient-centered medical home. *Ann Fam Med*. 2017 May;15(3):258-261. PMID: PMC5422088.
41. **Tsui JI**, Burt R, Thiede H, Glick SN. Utilization of buprenorphine and methadone among opioid users who inject drugs. *Subst Abus*. 2018 Jan 2;39(1):83-88. PMID: PMC6467071.\*
42. Simon CB, **Tsui JI**, Merrill JO, Adwell A, Tamru E, Klein JW. Linking patients with buprenorphine treatment in primary care: predictors of engagement. *Drug Alcohol Depend*. 2017 Dec 1;181:58-62. PMID: 29035705.
43. Owens MD, Ioannou GN, **Tsui JI**, Edelman EJ, Greene PA, Williams EC. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. *Drug Alcohol Depend*. 2018 Jul 1;188:79-85. PMID: PMC5999587.
44. Wagman JA, Samet JH, Cheng DM, Gnatienco N, Raj N, Blokhina E, Toussova OV, Forman LS, Lioznov D, **Tsui JI**. Female gender and HIV transmission risk behaviors among people living with HIV who have ever used injection drugs in St. Petersburg, Russia. *AIDS Behav*. 2018 Sep;22(9):2830-2839. PMID: PMC6128669.
45. Assoumou SA, Wang J, Tasillo A, Eftekhari Yazdi G, **Tsui JI**, Strick L, Linas BP. Hepatitis C testing and patient characteristics in Washington state's prisons between 2012 and 2016. *Am J Prev Med*. 2018 Nov 12. PMID: PMC6312183.
46. Frost MC, Matson TE, **Tsui JI**, Williams EC. Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and hepatitis C and/or HIV. *Drug Alcohol Depend*. 2018 Oct 30;194:288-295. PMID: PMC6312483.
47. James JR, Gordon LM, Klein JW, Merrill JO, **Tsui JI**. Interest in prescribing buprenorphine among resident and attending physicians at an urban teaching clinic. *Subst Abus*. 2018 Mar 26;1-3. PMID: 29578857.
48. Klein JW, Peacock S, **Tsui JI**, O'Neill SF, DesRoches CM, Elmore JG. Perceptions of primary care notes by patients with mental health diagnoses. *Ann Fam Med*. 2018 Jul;16(4):343-345. PMID: PMC6037508.
49. Gnatienco, N, Wagman JA, Cheng MD, Bazzi A, Raj A, Blokhina E, Toussova O, Forman LS, Lioznov D, Briden C, Sullivan M, Bryant K, Samet JH, **Tsui JI**. Serodiscordant partnerships and opportunities for pre-exposure prophylaxis among partners of women and men living with HIV in St. Petersburg, Russia. *PLoS One*. 2018 Nov 16;13(11):e0207402. PMID: PMC6239322.
50. **Tsui JI**, Miller CM, Scott JD, Corcoran MA, Dombrowski JC, Glick SN. Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle. *Drug Alcohol Depend*. 2019 Feb 1;195:114-120. Epub 2018 Dec 26. PMID: PMC6440747.\*
51. Colasanti J, Lira MC, Cheng DM, Liebschutz JM, **Tsui JI**, Forman LS, Sullivan M, Walley AY, Briden C, Root C, Podolsky M. Chronic opioid therapy in people living with Human Immunodeficiency Virus: patients' perspectives on risks, monitoring, and guidelines. *Clin Infect Dis*. 2019 Jan 7;68(2):291-297. PMID: PMC6594413
52. **Tsui JI**, Walley AY, Cheng DM, Lira MC, Liebschutz JM, Forman LS, Sullivan MM, Colasanti J, Root C, O'Connor K, Shanahan CW, Briden CL, del Rio C, Samet JH. Provider opioid prescribing practices and the belief that opioids keep people living with HIV engaged in care: a cross-sectional study. *AIDS Care*. 2019 Jan 11:1-5. PMID: PMC6625838
53. Geddes L, Iversen J, Wand H, Esmaili A, **Tsui J**, Hellard M, Dore G, Grebely J, Dietze P, Bruneau J, Prins M, Morris MD, Shoukry NH, Lloyd AR, Kim AY, Lauer G, Cox AL, Page K, Maher L; InC3 Collaborative. Sex discrepancies in the protective effect of opioid agonist therapy on incident hepatitis C infection. *Clin Infect Dis*. 2019 Feb 28. PMID: 30816419
54. Godersky ME, Saxon AJ, Merrill JO, Samet JH, Simoni JM, **Tsui JI**. Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. *Addict Sci Clin Pract*. 2019 Mar 13;14(1):11. doi: 10.1186/s13722-019-0139-3. PMID: PMC6417248\*

55. Lira MC, **Tsui JI**, Liebschutz JM, et al. Study protocol for the targeting effective analgesia in clinics for HIV (TEACH) study - a cluster randomized controlled trial and parallel cohort to increase guideline concordant care for long-term opioid therapy among people living with HIV. *HIV Res Clin Pract.* 2019 Apr;20(2):48-63. PMID: PMC6693587
56. Payne BE, Klein JW, Simon CB, James, JR, Jackson SL, Merrill JO, Zhuang R, and **Tsui JI**. Effect of lowering initiation thresholds in a primary care-based buprenorphine treatment program. *Drug Alcohol Depend.* 2019 May 1;200:71-77. PMID: 31103879
57. Price CJ, Merrill JO, McCarty RL, Pike KC, **Tsui JI**. A Pilot Study of Mindful Body Awareness Training as an Adjunct to Office-Based Medication Treatment of Opioid Use Disorder. *J Subst Abuse Treat.* 2019 May 23. PMID: 31174929
58. Merlin JS, Samet JH, Cheng DM, Lira MC, **Tsui JI**, Forman LS, Colasanti J, Walley AY, Del Rio C, Liebschutz JM. Marijuana Use and Its Associations With Pain, Opioid Dose, and HIV Viral Suppression Among Persons Living With HIV on Chronic Opioid Therapy. *J Acquir Immune Defic Syndr.* 2019 Oct 1;82(2):195-201. PMID: PMC6746234.
59. Litwin AH, Jost J, Wagner K, Heo M, Karasz A, Feinberg J, Kim AY, Lum PJ, Mehta SH, Taylor LE, **Tsui JI**, Pericot-Valverde I, Page K; HERO Study Group. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. *Contemp Clin Trials.* 2019 Oct 24:105859. PMID: 31669450
60. Banta-Green CJ, Floyd AS, Vick K, Arthur J, Hoeft TJ, **Tsui JI**. Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study. *Subst Abuse Rehabil.* 2019 Oct 22;10:57-67. PMID: PMC6815213
61. **Tsui JI**, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, Leroux BG, Merrill JO. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. *J Subst Abuse Treat.* 2019 Nov 18. PMID: 31810594\*
62. Godersky ME, Klein JW, Merrill JO, Blalock K, Saxon AJ, Samet JH, **Tsui JI**. Feasibility of a mobile health app for video directly observed therapy of buprenorphine among patients treated for opioid use disorders in an office-based setting. *In Press.*\*

\*Top publications, as selected by personal interest and impact factors

#### NOTABLE CITATIONS (SHAPED POLICY)

1. **Tsui JI**, Vittinghoff E, Shlipak MG, O'Hare AM. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. *J Am Soc Nephrol.* 2006;17:1168-74. PMID: 16524948.

Cited in: Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. *Kidney International.* 2007;72:247-259.

2. **Tsui JI**, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K. Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. *Drug Alcohol Depend.* 2009;105:160-3. PMID: PMC2849721.

Cited in: "Hepatitis C Virus Infection in Young Persons Who Inject Drugs", an Executive Summary presented February 26–27, 2013. The U.S. Department of Health and Human Services (HHS) Office of HIV/AIDS and Infectious Disease Policy, in partnership with the National Institutes of Health, the Centers for Disease Control and Prevention, the Substance Abuse and Mental Health Administration, and other federal agencies, convened a 2-day consultation to address the emerging epidemic of hepatitis C infection among young persons who inject drugs.

3. **Tsui JI**, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. *JAMA Intern Med.* 2014;174(12):1974-81. PMID: PMC4506774.

Cited in: the American Academy of Pediatrics Policy Statement on “Medication-Assisted Treatment of Adolescents With Opioid Use Disorders”, released August, 2016.

4. Carey K, Huang W, Linas BP, **Tsui JI**. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders. *J Subst Abuse Treat.* 2016 Jul;66:54-9. PMID: PMC5097249.

Cited in: NIH/NIDA “Director’s Report 2016,” by Dr. Nora Volkow

5. **Tsui JI**, Ko S, Krupitsky E, Lioznov D, Chaisson CE, Gnatienco N, Samet JH. Insights on the Russian HCV care cascade: Minimal HCV treatment for HIV/HCV co-infected PWID in St. Petersburg. *Hepatol Med Policy.* 2016;1. PMID: PMC5313079.

Cited in: “HIV and AIDS in Russia.” Global information and education on HIV and AIDS. Avert. 2017 June; Retrieved from [https://www.avert.org/professionals/hiv-around-world/eastern-europe-central-asia/russia#footnote64\\_h5jg21s](https://www.avert.org/professionals/hiv-around-world/eastern-europe-central-asia/russia#footnote64_h5jg21s)

6. **Tsui JI**, Herman DS, Kettavong M, Anderson BJ, Stein MD. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. *Pain.* 2011;152(11):2640-4. PMID: PMC3235744.

Cited in: Volkow ND, Koroshetz WJ. The role of neurologists in tackling the opioid epidemic. *Nat Rev Neurol.* 2019 May;15(5):301-305. doi: 10.1038/s41582-019-0146-8.

#### TEXTBOOK CHAPTERS

1. **Tsui, JI**. Breast Lump Evaluation. In: Doyle JP and Martin L. Ambulatory Medicine Casebook. Lippincott and Wilkins; 2001.
2. Hasbrouk L, **Tsui JI**. Chronic Pain Syndrome. In: Branch W. Office Practice of Medicine, Fourth Edition. Harcourt Health Sciences; 2003.

#### OTHER PUBLICATIONS

1. Samet JH, **Tsui JI**. Variations in prescription opioids and related harms: a key to understanding and effective policy. *Addiction.* 2014;109(2):183-5. PMID: 24422611

#### MANUSCRIPTS SUBMITTED/IN PREPARATION

1. Piske M, Thomson T, Krebs E, Hong N, Bruneau J, Greenland S, Gustafson P, Karim E, McCann L, Maclure M, Platt R, Socias E, **Tsui JI**, Wood E, Nosyk B. The comparative effectiveness of buprenorphine-naloxone versus methadone: a population-based observational study protocol. *BMJ Open.* Under review.
2. Merlin JS, Hamm M, De Abril Cameron F, Baker V, Brown DA, Cherry CL, Edelemen EJ, Evangeli M, Harding R, Josh J, Kemp HI, Lichius C, Madden VJ, Nkhoma K, O’Brien KK, Parker R, Rice A, Robinson-Papp J, Sabin CA, Slawek D, Scott W, **Tsui JI**, Uebelacker LA, Wadley AL, Goodin BR. The Global Task Force for Chronic Pain in People with HIV (PWH): Developing a research agenda in an emerging field. *AIDS.* Under review.

3. **Tsui JI**, Lapham G, Boudreau DM, Johnson E, Binswanger IA, Cunningham CO, Thakral M, Arnsten JH, Saxon AJ, Merrill JO, Samet JH, Bart G, Campbell CI, Bradley KA. Opioid use disorder among persons with Hepatitis C and HIV: Data from 6 health systems. In preparation.

#### ABSTRACTS

- A1. Gibbs C, **Tsui J**. A man newly diagnosed with HIV refuses to inform his spouse. Oral Clinical Vignette presented at the 26th SGIM National Meeting, 2003. Vancouver, BC.
- A2. **Tsui J**, Traub N, Koch-Levy N, Iverson C. Improving access to care for patients with chronic hepatitis C in an inner city hospital: Pairing general internists and specialists. Poster presentation at the 27th SGIM National Meeting, 2004. Chicago, IL
- A3. **Tsui J**, Pletcher M, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. Poster presentation at the 28<sup>th</sup> SGIM National Meeting, 2005. Chicago, IL.
- A4. Seal KH, Kral AH, Lorvick J, Gee L, **Tsui J**, Edlin BR. Among injection drug users interest is high, but access low to HCV antiviral therapy. Poster presentation at the 28<sup>th</sup> SGIM National Meeting, 2005. New Orleans, LA.
- A5. **Tsui J**, Vittinghoff E, Shlipak M, Rodriguez R, Inadomi J, O'Hare A. Hepatitis C seropositivity is associated with increased risk for developing end-stage renal disease. Oral presentation at the Bay Area Clinic Research Symposium, 2006. San Francisco, CA.
- A6. **Tsui JI**, Whooley MA, Monto A, Seal K, Tien PC, Shlipak MS. Association of hepatitis C virus seropositivity with inflammatory markers and outcomes in persons with coronary heart disease: Data from the Heart and Soul Study. Poster presentation at the 31th SGIM National Meeting, 2008. Pittsburgh, PA.
- A7. **Tsui JI**, Maselli J, Gonzales R. Patterns of race and insurance among national ambulatory visits for hepatitis C. Poster presentation at the 31th SGIM National Meeting, 2008. Pittsburgh, PA.
- A8. **Tsui JI**, Herman DM, Kettavong M, Anderson BJ, Stein MD. Hepatitis C virus infection and chronic pain in opioid-dependent injection drug users. Oral presentation at College on Problems of Drug Dependence 72<sup>nd</sup> Annual Scientific Meeting, 2010. Scottsdale, AZ.
- A9. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with illicit drug use in HIV-infected Russian drinkers. Oral presentation at College on Problems of Drug Dependence 74<sup>th</sup> Annual Scientific Meeting 2012. Palm Springs, CA.
- A10. Fuster D, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, **Tsui JI**. Chronic hepatitis C virus (HCV) infection is associated with all-cause mortality in a cohort of HIV-infected patients with alcohol problem. Poster presentation at the 20th Conference on Retroviruses and Opportunistic Infections, 2013. Atlanta, GA.
- A11. Fuster D, Cheng DM, Quinn EK, Bridden C, Kaku A, Saitz R, Freiberg M, Samet JH, **Tsui JI**. Inflammatory cytokines (IL-6, IL-10 and TNF-alpha) and mortality in a cohort of HIV-infected patients with alcohol problems. Oral presentation at the 20th Conference on Retroviruses and Opportunistic Infections, 2013. Atlanta, GA.
- A12. **Tsui JI**, Cheng DM, Coleman S, Blokhina E, Bridden C, Krupitsky E, Samet JH. Pain is associated with heavy drinking over time in HIV-infected Russian drinkers. Poster presentation at the 32<sup>nd</sup> Annual Scientific Meeting of the American Pain Society, 2013. New Orleans, LA.
- A13. **Tsui JI**, Samet JH, Alcorn MC, Mao J, Edwards RR. Differential predictors of self-reported pain and experimental pain tolerance among treated opioid addicts. Poster presentation at the 32<sup>nd</sup> Annual Scientific Meeting of the American Pain Society, 2013. New Orleans, LA.
- A14. **Tsui JI**, Samet JH, Liebschutz J, Alcorn M, Alford D, Mao J, Edwards RR. Depression, Pain catastrophizing and pain tolerance in opioid dependent patients. Poster presentation at the College on Problems of Drug Dependence 75th Annual Scientific Meeting 2013. June 17, 2013. San Diego, CA.

- A15. **Tsui JI**, Nader C, Pierson L, Labelle C, Pace CA, Samet JH. Integrating care for hepatitis C virus infection with office-based therapy for opioid dependence. Poster presentation at the 37<sup>th</sup> Annual Meeting of the Society of General Internal Medicine, April 25 2014.
- A16. **Tsui JI**, Cheng DM, Lira MC, Winter M, Alford D, Mao J, Edwards RR, Samet JH. Hepatitis C virus infection, HIV and pain sensitivity in opioid dependent patients. Oral presentation at the College on Problems of Drug Dependence 76<sup>th</sup> Annual Scientific Meeting, June 14 2014.
- A17. Samet JH, Krupitsky E, Wulach L, Chaisson C, **Tsui JI**. Hepatitis C Virus testing and treatment among HIV-infected injection drug users in St. Petersburg, Russia. Oral presentation at the College on Problems of Drug Dependence 76<sup>th</sup> Annual Scientific Meeting, June 14 2014.
- A18. **Tsui JI**, Evans JL, Lum PJ, Hahn JA, Page K. Opioid agonist therapy is associated with lower incidence of hepatitis C virus infection in young adult persons who inject drugs. Oral presentation at the American Association of Liver Disease (AASLD) annual meeting, November 2014. Boston MA.
- A19. **Tsui JI**, Cheng DM, Sisson EK, Briden C, Merlin JS, Saitz R, Samet JH. Pain and mortality among HIV-infected persons with alcohol problems. Poster at the 34th Annual Scientific Meeting of the American Pain Society, May 13-16, 2015. Palm Springs, CA.
- A20. **Tsui JI**, Lira M, Cheng DM, Winter MR, Edwards RR, Mao J, Samet JH. Inflammatory cytokines and pain in patients with treated opioid use disorders. Oral presentation at the College on Problems of Drug Dependence 77th Annual Scientific Meeting, June 16 2015.
- A21. Lira M, Cheng DM, Winter MR, Edwards RR, Samet JH, **Tsui JI**. Chronic pain, craving and recent opioid use among patients treated for opioid use disorders. Poster presentation at the College on Problems of Drug Dependence 77th Annual Scientific Meeting, June 15 2015.
- A22. **Tsui JI**, Cheng DM, Coleman SM, Blokhina E, Gnatienco N, Bryant K, Krupitsky E, Zvartau E, Samet JH. Pain, alcohol and sex risk behaviors among HIV-infected Russians. Poster presentation at the Research Society on Alcoholism 38<sup>th</sup> Annual Meeting, June 24 2015. San Antonio TX.
- A23. **Tsui JI**, Floyd A, Merrill J, Banta-Green C. Barriers to opioid agonist therapy among persons with problematic opioid use. Association for Medical Education and Research in Substance Use 39<sup>th</sup> Annual National Conference, November 6, 2015. Washington DC.
- A24. Gnatienco N, **Tsui JI**, Wagman JA, Cheng DM, Raj A, Blokhina E, Toussova O, Forman L, Lioznov D, Samet JH. Gender differences among people who inject drugs with regards to HIV transmission risk in St. Petersburg, Russia. Poster presentation at the 78th College on Problems of Drug Dependence Annual Scientific Meeting & NIDA International Forum, June 11-16, 2016. Palm Springs, CA. Poster presentation at the CHAART 2016 Scientific Meeting, February 7-9, 2016 Washington DC.
- A25. **Tsui JI**, Glick SN, Thiede H. Utilization of opioid agonist therapy among persons who inject drugs in the Seattle area, Poster presentation at the College on Problems of Drug Dependence 78th Annual Scientific Meeting, June 15 2016.
- A26. **Tsui JI**, Mirzazadeh A, Hahn JA, Maher L, Bruneau J, Grebely J, Hellard M, Kim AY, Shoukry NH, Cox AL, Prins M, Dore G, Lauer G, Lloyd A, Page K. The effects of alcohol on spontaneous clearance of acute hepatitis c virus infection in females versus males. Poster presentation at the 5<sup>th</sup> International Symposium on Hepatitis Care in Substance Users, September 6-9, 2016. Oslo, Norway.
- A27. **Tsui JI**, Peavy M, James J, Merrill JO, Paquin J, Folz B, Chew L, Carney M. An assessment of health care needs among patients and providers in preparation for implementation of on-site primary care services in an opioid treatment program. Oral presentation at the Association for Medical Education and Research in Substance Abuse (AMERSA) 40<sup>th</sup> Annual National Conference, November 3-5, 2016. Washington, DC.
- A28. Gordon LM, James JR, Klein JW, Merrill JO, **Tsui JI**. Attitudes toward buprenorphine among staff versus providers in an urban hospital-based primary care clinic. Poster presentation at the Association for Medical Education and Research in Substance Abuse (AMERSA) 40th Annual National Conference, November 3-5, 2016. Washington, DC.

- A29. James JR, Gordon LM, Klein JW, Merrill JO, **Tsui JI**. Interest in prescribing buprenorphine among residents and attending physicians at an urban hospital-based primary care clinic. Poster presentation at the Association for Medical Education and Research in Substance Abuse (AMERSA) 40th Annual National Conference, November 3-5, 2016. Washington, DC.
- A30. **Tsui J**, Wagman J, Cheng D, Gnatienco N, Blokhina E, Forman L, Bazzi A, Lioznov D, Samet J. Opportunities for and awareness of pre-exposure prophylaxis among HIV-infected Russian women and men. Poster presentation at the 10th Annual InWomen's Group Conference & NIDA International Forum, June 16, 2017. Montreal, Canada.
- A31. Assoumou SA, Wang J, **Tsui JI**, Tasillo A, Eftekhari Yazdi G, Linas BP, Strick L. Characterization of a population with hepatitis C virus infection in a U.S. state prison. Poster presentation at the 6th International Symposium on Hepatitis Care in Substance Users (INHSU), September 6-8, 2017. Jersey City, New York.
- A32. Darnton J, Klein JW, **Tsui JI**. Implementation of Buprenorphine Training for Internal and Family Medicine Residents. Poster Presentation at the Association for Multidisciplinary Education and Research in Substance use and Addiction 42nd Annual National Conference, November 2-4, 2017, Washington, DC.
- A33. Geddes L, Esmacili A, Iversen J, **Tsui J**, Bruneau J, Shoukry N, Hellard M, Dietze P, Prins M, Morris M, Lloyd A, Maher L, Page K, on behalf of the InC3 Collaboration. Attenuated protective effect of opioid agonist therapy on hepatitis C incidence among females. Oral presentation at the 22<sup>nd</sup> International Workshop on HIV and Hepatitis Observational Databases, March 22-24, 2018. Fuengirola, Spain.
- A34. **Tsui JI**, Godersky ME, Merrill JO, Samet JH. Perspectives on Buprenorphine Adherence and Use of mHealth Technology to Address Barriers. Poster presentation at the 49<sup>th</sup> Annual American Society of Addiction Medicine Conference, April 13, 2018. San Diego, CA.
- A35. Payne BE, Klein JW, Merrill JO, **Tsui JI**. Ceasing to Require Stimulant Abstinence Increases Engagement in Buprenorphine Treatment. Poster presentation at the 49<sup>th</sup> American Society of Addiction Medicine Annual Conference, April 13<sup>th</sup>, 2018, San Diego, CA
- A36. **Tsui JI**, Lapham G, Boudreau DM, Johnson E, Binswanger IA, Cunningham CO, Thakral M, Arnsten JH, Saxon AJ, Merrill JO, Samet JH, Bart G, Campbell CI, Bradley KA. Opioid use disorder among persons with Hepatitis C and HIV: Data from 8 health systems. Oral presentation at the College on Problems of Drug Addiction Annual Meeting, June 12, 2018. San Diego, CA.
- A37. Barbosa-Leiker C, Campbell A, Hatch-Maillette M, Lapham G, Boudreau DM, Thakral M, **Tsui J**, Yarborough BJ, Arnsten J, Binswanger I, Stotts A, Loree A, Braciszewski J, Glass J, Horigian V; Hutcheson R, Campbell C, Bart G, Bradley K. Sex differences in co-occurring substance use, mental health and pain disorders, in primary care patients diagnosed with opioid use disorders. Oral presentation at the College on Problems of Drug Addiction Annual Meeting, June 13, 2018. San Diego, CA.
- A38. Thakral M, Lapham G, Bobb J, **Tsui J**, Boudreau DM, Campbell C, Arnsten J, Liebschutz JM, Stotts A, Braciszewski J, Saxon A, Bradley K. Prevalence of pain conditions among persons with an opioid use disorder diagnosis in a primary care population. Oral presentation at the College on Problems of Drug Addiction Annual Meeting, June 13, 2018. San Diego, CA.
- A39. Wagman J, Matsuzaki M, Gnatienco N, Metsch LR, Del Rio C, Feaster DJ, Delaney JAC, Dong X, Kahana S, Crane HM, Chandler R, Elliott JC, Altice F, Lucas G, Mehta S, Hirsch-Moverman Y, El-Sadr W, Quan V, Springer S, Pitpitan E, **Tsui JI**, Samet JH. Associations between hazardous alcohol use, antiretroviral receipt and viral suppression in HIV-positive people who inject drugs in the U.S., India, Russia and Vietnam. Poster presentation at 41st Annual RSA Scientific Meeting, June 16-20, 2018. San Diego, CA.
- A40. Taylor LE, Feinberg J, Norton B, Kim A, Page K, Lum P, Mehta S, **Tsui J**, Litwin A. Real World Direct Acting Antiviral (DAA) Outcomes Among People Who Inject Drugs: Hepatitis C Real Options (HERO). Poster Presentation at the 7th International Symposium on Hepatitis Care in Substance Users,



- International Network on Hepatitis in Substance Users (INHSU), September 19 – 21, 2018, Lisbon, Portugal.
- A41. Godersky ME, Merrill JO, Saxon AJ, Samet JH, **Tsui JI**. Feasibility of a mobile health app for video directly observed therapy of buprenorphine among patients treated for opioid use disorders in an office-based setting. Oral Presentation at the Association for Multidisciplinary Education and Research in Substance use and Addiction 42<sup>nd</sup> Annual National Conference, November 8, 2018, San Francisco, CA
- A42. Klein JW, Hermsen JL, **Tsui JI**. Linking Infective Endocarditis Patients with Opioid Use Disorder to Addiction Treatment After Valve Replacement. Poster Presentation at the Association for Multidisciplinary Education and Research in Substance use and Addiction 42<sup>nd</sup> Annual National Conference, November 8, 2018, San Francisco, CA
- A43. James JR, Chan H, Jackson SI, Sweney G, **Tsui JI**. Primary care based management of chronic hepatitis C by internal medicine trainees. Poster presentation at the Association of Multidisciplinary Education and Research in Substance use and Addiction 42<sup>nd</sup> Annual National Conference, November 8, 2018, San Francisco, CA
- A44. **Tsui JI**, Bendiks S, Cheng DM, Blokhina E, Vetrova M, Verbitskaya E, Gnatienco N, Krupitsky E, Samet JH. Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for pain among HIV-positive Russians with chronic pain and prior heavy drinking. Oral Presentation at the 81<sup>st</sup> Annual Meeting of the College on Problems of Drug Dependence, Tuesday, June 18, San Antonio, TX.
- A45. del Rio C, **Tsui J**, Cheng D, Colasanti J, Liebschutz J, Lira M, Forman L, Shanahan C, Root C, Briden C, Outlaw K, Abrams C, Carroll J, Walley A, Samet J. Targeting Effective Analgesia in Clinics for HIV (TEACH): a Randomized Controlled Trial (RCT) to Improve Satisfaction, Confidence, and Trust around Chronic Opioid Therapy in HIV Care. Poster presentation at the International AIDS Society Meeting, Monday, 22 July 2019, Mexico City, Mexico.

## 16. INVITED LECTURES AND PRESENTATIONS

- 2004 Invited presentation: “Screening for Hepatitis C” at Primary Care Grand Rounds, Grady Memorial Hospital, Emory University 2004
- 2008 Invited presentation: “Hepatitis C and Kidney Disease Outcomes” at Primary Care Grand Rounds, Mt. Sinai School of Medicine, NY, NY 2008
- 2011 Invited presentation: “Integrating Care for Hepatitis C Virus Infection in Patients Receiving Office-Based Therapy for Opioid Dependence” part of the workshop “Integrating Care for Alcohol and Drug Use in Primary Care: Challenges and Opportunities” at the Addiction Health Services Research Conference, October 4, 2011, Fairfax, VA
- 2012 Invited presentation: “Hepatitis C Virus Infection in Injection Drug Users” at the NIDA-sponsored Boston University Fellow Immersion Training (FIT) Program in Addiction, May 2-5, 2012, Chatham MA
- 2013 Invited presentation: “Chronic Hepatitis C Virus Infection: Not Just a Liver Disease” in NIDA sponsored Symposium “Caring for the Hepatitis C Virus Infected Patient with Co-morbidities” at the 44<sup>th</sup> American Society of Addiction Medicine Annual Medical-Scientific Conference, April 27, 2013, Chicago, IL
- 2013 Workshop/Invited presentation: “Oh Say Can You C: Training Generalists for Their Roles as Front Line Hepatitis C Screeners, Counselors, and Treaters in the New Era of Birth Cohort Screening” at Society for General Internal Medicine 36<sup>th</sup> Annual Meeting, April 26, 2013, in Denver, Colorado
- 2014 Panel discussion: “Coping with Addictions: A Patient and Team’s Journey Together” at Department of Medicine Medical Grand Rounds, Schwartz Center Rounds, Boston University March 14, 2014

- 2014 Workshop/Invited presentation: “Impact of Hepatitis C Virus Infection on Quality of Life and Pain” in NIDA sponsored Symposium “Neuropsychiatric Complications of HCV among Drug Users” accepted to the 45<sup>th</sup> American Society of Addiction Medicine Annual Medical-Scientific Conference, April 11 2014, Orlando, FL
- 2014 Invited presentation: “Hepatitis C Virus Infection for the General Internist: Future Challenges and Opportunities” at General Internal Medicine Grand Rounds, Boston Medical Center May 7, 2014, Boston, MA
- 2015 Invited presentation: “Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users” for a Project Echo Hepatitis C Telemedicine conference, March 10, 2015, Seattle, WA
- 2015 Invited presentation: “Pain in patients with HCV & HIV & drug use comorbidity” at Pain and Addiction: Research and Clinical Practice Pre-Conference Session; American Association for Treatment of Opioid Dependence National Conference March 29, 2015, Atlanta, GA
- 2015 Invited presentation: “Organizing and Managing your CV” for Department of Medicine’s Fellows Course, “Surviving and Thriving During the Research Years”, July 29, 2015, Seattle, WA
- 2015 Invited presentation: “Office Based Treatment of Opioid Use Disorders with Buprenorphine” for Community Health Outreach Worker (CHOW) presentation, Public Health – Seattle & King County, November 17, 2015, Seattle Counseling Services, Seattle, WA
- 2016 Invited presentation: “Hepatitis C: A Shifting Paradigm for Patients and Providers” for the HMC Adult Medicine Clinic “Brown Bag” Lectures, November 29, 2016, Seattle, WA
- 2016 Invited presentation: “Hepatitis C: A Shifting Paradigm for Patients and Providers” at Resident Conference/Academic Half-Day, December 1, 2016, Seattle, WA
- 2017 Invited presentation: “Implementing the Massachusetts Model for Opioid Use Disorder Treatment at Harborview” at the 19<sup>th</sup> Annual Fundamentals of Addiction Medicine Conference jointly sponsored by Providence Regional Medical Center Everett and Swedish Hospital, March 2, 2017
- 2017 Panel discussion: “Hub and Spoke for Delivery of MAT” at Emerging Practices on Collaborative Care Management of Chronic Pain: Equipping Primary Care and the Community to Manage an Epidemic, Collaborative Care Symposium 2017, June 14, 2017, SeaTac, WA
- 2018 Panel discussion: “Substance use” at Social Determinants of Health, UW/HMC Social Emergency Medicine Conference Day, March 8, 2018, Seattle, WA
- 2018 Invited presentation “Hepatitis C Elimination and Treatment of HCV Infection Among Persons Who Inject Drugs” for Symposium “The ID Specialist and the Opioid Epidemic: What You Need to Know” IDWeek, San Francisco, Infectious Disease Society of America, October 5, 2018
- 2018 Invited presentation “Practical aspects of caring for patients who inject drugs” and “Treatment of Opioid Use Disorder” at American College of Physicians (ACP) Washington Chapter Scientific Meeting, November 1-3, 2018, Seattle, WA
- 2019 Panel discussion: “HIV, HCV, Opioids, and Meth Use in the Pacific Northwest: Challenges and Opportunities, with special guest Evan Wood” at a Symposium on Substance Use and HIV hosted by UW/FredHutch CFAR Behavioral Science Core, March 13, 2019, Seattle, WA
- 2019 Invited presentation “An Overview of Non-Injection Drug Use and Hepatitis C” for the HepCure Tele-Education Webinar Series, March 16, 2019, presented from Seattle, WA
- 2019 Panel discussion: “Ask a Medical Provider about Hepatitis C and the Medications that can Cure It” for the HEP C Free WA community event, May 18, 2019, Seattle, WA
- 2019 Invited presentation “Addressing Treatment Gaps to Overcome the Crisis of Opioid Use Disorders and Hepatitis C” at the University of Washington School of Medicine, Department of Medicine Grand Rounds, May 30, 2019, Seattle, WA

- 2019 Panel discussion: “Medications for Opioid Use Disorders and Hepatitis C” for Northwest Addiction Technology Transfer Center webinar, June 26, 2019, presented from Seattle, WA
- 2019 Invited presentation “The intersection of MOUD work with important health concerns for individuals who smoke and inject drugs.” at Washington Recovery Helpline MOUD Meeting, December 4, 2019, Seattle, WA

**17. MENTORSHIP**

2011-2012	Lidia Meshesha, PhD Candidate	1 publication (see bibliography)
2011-2013	Daniel Fuster, MD, PhD and International Fellow	4 publications (see bibliography)
2011-present	Marlene Lira, research coordinator	1 publication (see bibliography)
2012-2013	Denise Crooks, research coordinator	1 publication (see bibliography)
2012-2013	Ji Mao, MSc candidate	Master’s thesis
2012-2016	Katelyn Carey, MS, MPH and MD Candidate	Presentation at meeting, 1 publication (see bibliography)
2015-2017	Claire Simon, MD student	1 publication (see bibliography)
2016-2018	Jennifer Wagman, PhD	2 conference abstracts, 2 publications (see bibliography)
2016-present	Bjorn Payne, MD student	1 conference abstract, 1 publication (see bibliography)
2016-present	Jocelyn James, MD junior attending	2 conference abstracts, 1 publication (see bibliography)
2016-present	Jared Klein, MD junior attending	1 publication, 2 conference abstracts, 1 grant
2017-present	James Darnton, MD junior attending	1 conference abstract
2018-present	Natasha Ludwig-Baron, PhD candidate	1 conference abstract
2018-present	Belle Ngo, MD student	1 conference abstract, manuscript submitted
2019-present	Julian Takagi-Stewart, undergraduate, pre-med	1 conference/poster abstract
2019-present	Maria Corcorran, MD (fellow)	2 conference abstracts
2019-present	Elenore Bhatraju, MD MPH	2 papers in preparation